Overview

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

Status:
Not yet recruiting

Trial end date:
2022-05-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and toxicity of patients treated with hypofractionated radiotherapy for limited metastatic NSCLC harboring sensitizing EGFR mutations after first line TKI therapy. An exploratory biomarker analysis in blood and tumor samples is also planned.

Phase:

Phase 2

Details

Lead Sponsor:

First People's Hospital of Hangzhou

Treatments:

Erlotinib Hydrochloride
Gefitinib